189 related articles for article (PubMed ID: 29059492)
1. Phase I study of single-agent ribociclib in Japanese patients with advanced solid tumors.
Doi T; Hewes B; Kakizume T; Tajima T; Ishikawa N; Yamada Y
Cancer Sci; 2018 Jan; 109(1):193-198. PubMed ID: 29059492
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors.
Geoerger B; Bourdeaut F; DuBois SG; Fischer M; Geller JI; Gottardo NG; Marabelle A; Pearson ADJ; Modak S; Cash T; Robinson GW; Motta M; Matano A; Bhansali SG; Dobson JR; Parasuraman S; Chi SN
Clin Cancer Res; 2017 May; 23(10):2433-2441. PubMed ID: 28432176
[No Abstract] [Full Text] [Related]
3. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas.
Infante JR; Cassier PA; Gerecitano JF; Witteveen PO; Chugh R; Ribrag V; Chakraborty A; Matano A; Dobson JR; Crystal AS; Parasuraman S; Shapiro GI
Clin Cancer Res; 2016 Dec; 22(23):5696-5705. PubMed ID: 27542767
[TBL] [Abstract][Full Text] [Related]
4. Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer.
Yap YS; Chiu J; Ito Y; Ishikawa T; Aruga T; Kim SJ; Toyama T; Saeki T; Saito M; Gounaris I; Su F; Ji Y; Han Y; Gazdoiu M; Masuda N
Cancer Sci; 2020 Sep; 111(9):3313-3326. PubMed ID: 32619077
[TBL] [Abstract][Full Text] [Related]
5. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
Tripathy D; Im SA; Colleoni M; Franke F; Bardia A; Harbeck N; Hurvitz SA; Chow L; Sohn J; Lee KS; Campos-Gomez S; Villanueva Vazquez R; Jung KH; Babu KG; Wheatley-Price P; De Laurentiis M; Im YH; Kuemmel S; El-Saghir N; Liu MC; Carlson G; Hughes G; Diaz-Padilla I; Germa C; Hirawat S; Lu YS
Lancet Oncol; 2018 Jul; 19(7):904-915. PubMed ID: 29804902
[TBL] [Abstract][Full Text] [Related]
6. Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study.
Abdul Razak AR; Bauer S; Suarez C; Lin CC; Quek R; Hütter-Krönke ML; Cubedo R; Ferretti S; Guerreiro N; Jullion A; Orlando EJ; Clementi G; Sand Dejmek J; Halilovic E; Fabre C; Blay JY; Italiano A
Clin Cancer Res; 2022 Mar; 28(6):1087-1097. PubMed ID: 34921024
[TBL] [Abstract][Full Text] [Related]
7. Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients.
Rascon K; Flajc G; De Angelis C; Liu X; Trivedi MV; Ekinci E
Ann Pharmacother; 2019 May; 53(5):501-509. PubMed ID: 30522347
[TBL] [Abstract][Full Text] [Related]
8. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors.
Ando Y; Inada-Inoue M; Mitsuma A; Yoshino T; Ohtsu A; Suenaga N; Sato M; Kakizume T; Robson M; Quadt C; Doi T
Cancer Sci; 2014 Mar; 105(3):347-53. PubMed ID: 24405565
[TBL] [Abstract][Full Text] [Related]
9. Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Burris HA
Expert Rev Anticancer Ther; 2018 Mar; 18(3):201-213. PubMed ID: 29457921
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
Hortobagyi GN; Stemmer SM; Burris HA; Yap YS; Sonke GS; Paluch-Shimon S; Campone M; Blackwell KL; André F; Winer EP; Janni W; Verma S; Conte P; Arteaga CL; Cameron DA; Petrakova K; Hart LL; Villanueva C; Chan A; Jakobsen E; Nusch A; Burdaeva O; Grischke EM; Alba E; Wist E; Marschner N; Favret AM; Yardley D; Bachelot T; Tseng LM; Blau S; Xuan F; Souami F; Miller M; Germa C; Hirawat S; O'Shaughnessy J
N Engl J Med; 2016 Nov; 375(18):1738-1748. PubMed ID: 27717303
[TBL] [Abstract][Full Text] [Related]
11. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.
Zangardi ML; Spring LM; Blouin GC; Bardia A
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1169-1176. PubMed ID: 28875723
[TBL] [Abstract][Full Text] [Related]
12. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Bautista F; Paoletti X; Rubino J; Brard C; Rezai K; Nebchi S; Andre N; Aerts I; De Carli E; van Eijkelenburg N; Thebaud E; Corradini N; Defachelles AS; Ducassou S; Morscher RJ; Vassal G; Geoerger B
J Clin Oncol; 2021 Nov; 39(32):3546-3560. PubMed ID: 34347542
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer.
Curigliano G; Criscitiello C; Esposito A; Intra M; Minucci S
Expert Opin Drug Metab Toxicol; 2017 May; 13(5):575-581. PubMed ID: 28395543
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors.
Seetharam M; Norman A; Allred J; Kong J; Opyrchal M; Ma WW; Lou Y; Dy GK; Mahipal A; Weroha J; Wahner-Hendrickson A; Reid JM; Adjei AA
Res Sq; 2024 Apr; ():. PubMed ID: 38746220
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Fujiwara Y; Tamura K; Kondo S; Tanabe Y; Iwasa S; Shimomura A; Kitano S; Ogasawara K; Turner PK; Mori J; Asou H; Chan EM; Yamamoto N
Cancer Chemother Pharmacol; 2016 Aug; 78(2):281-8. PubMed ID: 27312735
[TBL] [Abstract][Full Text] [Related]
16. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.
Curigliano G; Gómez Pardo P; Meric-Bernstam F; Conte P; Lolkema MP; Beck JT; Bardia A; Martínez García M; Penault-Llorca F; Dhuria S; Tang Z; Solovieff N; Miller M; Di Tomaso E; Hurvitz SA
Breast; 2016 Aug; 28():191-8. PubMed ID: 27336726
[TBL] [Abstract][Full Text] [Related]
17. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Sonke GS; Hart LL; Campone M; Erdkamp F; Janni W; Verma S; Villanueva C; Jakobsen E; Alba E; Wist E; Favret AM; Bachelot T; Hegg R; Wheatley-Price P; Souami F; Sutradhar S; Miller M; Germa C; Burris HA
Breast Cancer Res Treat; 2018 Feb; 167(3):659-669. PubMed ID: 29058175
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial.
Goel S; Pernas S; Tan-Wasielewski Z; Barry WT; Bardia A; Rees R; Andrews C; Tahara RK; Trippa L; Mayer EL; Winer EP; Spring LM; Tolaney SM
Clin Breast Cancer; 2019 Dec; 19(6):399-404. PubMed ID: 31235441
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
[TBL] [Abstract][Full Text] [Related]
20. A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study.
DeWire MD; Fuller C; Campagne O; Lin T; Pan H; Young Poussaint T; Baxter PA; Hwang EI; Bukowinski A; Dorris K; Hoffman L; Waanders AJ; Karajannis MA; Stewart CF; Onar-Thomas A; Fouladi M; Dunkel IJ
Clin Cancer Res; 2021 May; 27(9):2442-2451. PubMed ID: 33547201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
